

#1642

CHAPTER 12

Recent Advances in Hepatic Transplantation at the University of Pittsburgh

Kareem Abu-Elmagd, Oscar Bronsther, Ashok Jain, William Irish, Hector Ramos, Ignazio R. Marino, Forrest Dodson, Rick Selby, Howard Doyle, Hiroyuki Furukawa, Timothy Gayowski, Bakr Nour, Jorge Reyes, George Mazariegos, Antonio Pinna, Abdul Rao, Paulo Fontes, Adrian Casavilla, Nicolas Jabbour, Wallace Marsh, Juan Madariaga, Anthony J. Demetris, Andreas Tzakis, Satoru Todo, Shun Iwatsuki, John J. Fung, and Thomas E. Starzl

*University of Pittsburgh Medical Center
Pittsburgh Transplant Institute
Pittsburgh, Pennsylvania*

We recently achieved 4 major advances in clinical hepatic transplantation at our center: first, the introduction and demonstration of the superior therapeutic index of the new immunosuppressive drug FK 506; second, the feasibility (with the aid of this drug) of combined liver-intestinal and multivisceral transplantation for patients with hepatointestinal failure; third, 2 attempts at hepatic xenotransplantation; and fourth, beginning attempts to induce donor-specific nonreactivity with adjuvant bone

marrow more rapidly. These studies will be addressed separately because of the unique design of each and the heterogeneity of the enrolled patient population. The survival curves for both patients and grafts were estimated by the Kaplan-Meier (product-limit) method and the comparison among the different cohorts within each population was done by the generalized Wilcoxon (Breslow) test.

LIVER - PITTSBURGH

CLINICAL EVOLUTION OF FK506: 4 YEARS EXPERIENCE

Since its discovery in 1983 and before its initial clinical use in February of 1989, the novel immunosuppressive drug FK506 underwent extensive in-vitro and animal studies (1,2). It was first used to salvage liver allografts that were failing because of rejection despite state-of-the-art treatment with conventional immunosuppression (3). The encouraging results of the rescue trial (4) justified the evaluation of FK506 as the primary immunosuppressant for our liver allograft recipients (5). Rather than summarizing our overall clinical experience with hepatic transplantation, we will focus on the therapeutic efficacy of FK506 among primary liver allograft recipients. The biocharacteristics, pharmacokinetics, and methods of assay of FK506 are fully described elsewhere (6-10).

MATERIALS AND METHODS

Patient Population

From August 18, 1989 through August 1, 1993, 1,153 consecutive patients underwent primary liver transplantation and received FK506 as the primary immunosuppressive agent. The patient characteristics are summarized in Table 1. Of the 1,153 recipients, 84% were adults and 16% were children. The mean age was 51±12 years (range: 18-76) for adults and 6±6 years (range: 0.2-17.8) for children. Of the adult patients 251 (26%) were over 60 years of age. The indications for liver transplantation based upon the histopathologic diagnosis of the native liver disease are given in Table 2. Parenchymal

Immunosuppression

From the outset, FK506 was used for all patients. The early phase of the study was carried out during the learning curve in which the daily induction doses were 2 or 3 times greater than those currently recommended (8, 13-15). Our present policy is to give FK506 initially intravenously as a continuous infusion at a dose of 0.05 mg/kg/day. The conversion from intravenous to oral therapy is usually made without any overlap with a starting oral dose of 0.1-0.15 mg/kg every 12 hours. Dose adjustments during both the intravenous or the oral administration of the drug were dictated by FK506 plasma trough levels, documentation of rejection, presence of adverse drug reactions with special emphasis of nephrotoxicity and neurotoxicity, evidence of infection, and functional status of the graft (13).

Immediately after graft reperfusion, one gram of methylprednisolone was administered intravenously. A daily dose of 20 mg of prednisone was started and reduced in 2 or 4 weeks in the absence of rejection. Thereafter, prednisone was weaned and frequently discontinued. The first 63 patients and those who had a strong positive cytotoxic crossmatch were given a 5-day steroid taper beginning at 200 mg/day for the first postoperative day with reduction of 40 mg/day until 20 mg/day was reached on the sixth day. Steroid doses were scaled down for children. Prostaglandin E₁ (prostin[®]) was added to the immunosuppressive cocktail of some patients during the first postoperative week (16). A low dose of azathioprine (0.5-2 mg/kg/day) was given to about 10% of the patients at some time during the postoperative period.

When rejection occurred, it was treated with an increased maintenance dose of FK506 and a one gram bolus of either methylprednisolone or hydrocortisone. A steroid recycle and/or a 5-day course of OKT₃ (5-10 mg/




Figure 1. The Kaplan-Meier (actuarial) patient and graft survival for primary liver allograft recipients who received FK506 as the primary immunosuppressive drug therapy.

day) was given to patients with moderate to severe rejection episodes.

RESULTS

Total Population

Of the 1,153 liver recipients, 233 (20%) patients have died for reasons summarized in Table 4. With a mean (\pm SD) follow-up of 22 ± 15 months (range: 3-49), the overall patient actuarial survival rates were 90%, 87%, 83%, and 75%, at 3, 6, 12 and 48 months, respectively (Fig. 1). With a total of 1,308 liver allografts, 155 (13%) failed. Rejection was the cause of failure of only 6 grafts (4%). The overall graft survival was 81%, 78%, 74%, and 65% at 3, 6, 12, and 48 months respectively (Fig. 1). The difference between patient and graft survival emphasizes the survival benefit of retransplantation.

Randomized versus Nonrandomized Groups

As expected, the highly selected randomized group ($n=79$) had significantly better patient ($p=0.006$) and graft ($p=0.001$) survival compared with the nonrandomized patients ($n=533$) who were excluded from the randomized study (Fig. 2). The 2-year patient survival was 91% versus 76% with a graft survival rate of 88% versus 67%. The survival difference between the 2 groups reflects the cumulative detrimental effect of the exclusion criteria that were used for randomization.

Table 4. Causes of death after primary liver transplantation under FK506 therapy.

	n	(%)
Fulminant infection	99	(9)
Graft failure	24	(2)
Malignancy	21	(2)
Cardiovascular	18	(1)
Others	46	(4)
Unknown	25	(2)
Total	233	(20)




Figure 4. Patient survival after liver transplantation stratified according to the medical urgency for surgery as defined by the standard criteria of the United Network for Organ Sharing (UNOS).

Primary Liver Disease

Patients with either parenchymal or cholestatic liver disease had similar and high long-term survival rates with FK506-based immunosuppression (Fig. 5). The recent achievement of a high posttransplant survival rate (82% at 12 months) for patients with fulminant hepatic failure is attributed to the current monitoring of intracerebral blood flow and prevention of excess intracranial pressure in addition to the therapeutic advantage of FK506. As expected, recipients with a preoperative diagnosis of primary hepatic malignancy had the lowest long-term survival: 72% at one year and 59% at 2 years. The common cause of patients' death was tumor recurrence despite the utilization of pretransplant intra-arterial chemotherapy in some of these patients with or without posttransplant systemic chemotherapy.

Recurrence of Viral B Hepatitis

In a series of 78 consecutive patients with hepatitis B viral (HBV)-related diseases, 56% had disease recurrence with a median follow-up of 24 months. Those who have higher levels of HBV replications ($n=8$) as assessed by the presence of HBe antigen positivity, experienced a higher rate of disease recurrence (88%), and half of them ($n=4$) died of recurrent hepatitis. The use of hepatitis B immune globulin did not prevent disease recurrence but may have delayed its clinical onset.




Figure 5. Survival of FK506 primary liver allograft recipients stratified according to the pathology of the primary liver disease.

Retransplantation

The need for graft replacement was significantly reduced with the use of FK506 (12%). Patient survival after retransplantation was 75% at 3 months and 54% at 2 years (Fig. 6).

Rejection

The incidence and treatment of liver allograft rejection under FK506 has been reported elsewhere (17). In summary, greater than 50% of the liver recipients were rejection free and nearly half of them were steroid free





Figure 6. The actuarial patient survival after retransplantation.



The management strategy for these unique liver recipients is described comprehensively in our recent publications (31, 32). The basic immunosuppressive drug therapy was FK506 in addition to steroids and prostaglandin E₁. Augmented immunosuppression was initiated during rejection episodes, based upon severity. A steroid bolus was given and FK506 dosage was increased when this was possible without nephrotoxicity. A steroid recycle for 5 days and/or a 7-day course of DKT, were backup options.

RESULTS

Patient Survival

During potential follow-ups of 6-39 months and as of October 1993, 9 (33%) of the 27 patients died: 8/21 combined liver and intestine, and 1/6 multivisceral. The causes of the 9 deaths were either technical complications (n=3), opportunistic infections (n=2), uncontrolled graft rejection (n=2), or disseminated posttransplant lymphoproliferative disease (PTLD) (n=2).

Six of the 8 mortalities after combined liver and intestinal transplantation were of children. Enteric and/or biliary leaks were responsible for 3 deaths. The other 3 were caused by respiratory syncytial viral pneumonia, refractory acute rejection, or PTLD (one example each). One of the 2 liver-intestine adult recipients died of

hepatorenal failure combined with chronic rejection and the other succumbed to disseminated coccidiomycosis. The only death in the multivisceral series was caused by PTLD which was diagnosed at autopsy 49 days posttransplantation.

The actual survival rate for the 27 patients at 3, 6, 12, and 24 months was 82%, 79%, 74%, and 69%, respectively (Fig. 7). The mean follow-up period was 16 ± 12 months for liver plus intestine and 11 ± 8 months for multivisceral recipients. At 3 months, the survival rate for the combined liver-intestine recipients was 81% and 86% for the multivisceral recipients. At one year following transplantation, these estimates were 71% and 86%, respectively. At 2 years, the actual survival rate was 65% for the combined liver intestinal recipients and 86% for those who received multivisceral grafts.

Graft Survival

The estimated actuarial survival for all of the grafts (n=28) was 76%, 76%, 71%, and 67% at 3, 6, 12, and 24 months, respectively (Fig. 8). Graft survival was higher during the entire follow-up period for the multivisceral cases compared to those with combined liver-intestine. All but one graft was lost due to patient's death. The only graft removed at reoperation was a liver-intestine transplanted to a child across a strong positive cytotoxic crossmatch. Although graft removal

CLINICAL XENOTRANSPLANTATION

MATERIALS AND METHODS

In June 1992 and January 1993, 2 male patients aged 35 and 62 years, with end-stage liver disease due to chronic B viral active hepatitis had their cirrhotic livers replaced with baboon livers (33, 34). These efforts were prompted by the worldwide shortage of donor organs and by evidence that baboon livers would be resistant to the hepatitis B virus that reinfects most hepatic allografts. Extensive infectious surveillance was performed for both donors. Both recipients had ABO-compatible grafts. The conventional lymphocytotoxic crossmatch of both recipient sera to their donor lymphocytes was positive in both cases but negative after dithiothreitol treatment. A full description of both donors and recipients has been published elsewhere (33, 34).

The surgical techniques were adapted from hepatic allotransplantation (35). Although the baboon donors were large, their body weights were only 40% of the recipients, necessitating the so-called piggyback operation which leaves the recipient vena cava intact. The surgical procedure in both cases was satisfactory initially and during the postoperative course, there was radiologic and histopathologic evidence of liver regeneration and increased graft volume (33, 34).

The immunosuppressive cocktail used for prevention and control of rejection of the 2 hepatic xenografts was made by FK506, steroids, cyclophosphamide, and prostaglandin E₁. Doses and routes of administration are shown in Figures 9 and 10. Detailed descriptions of the immunosuppressive therapy and drug blood levels were recently reported elsewhere (34).

RESULTS

The first recipient awoke promptly from anesthesia, resumed diet and ambulation, and was jaundice-free for most of the 70 days of survival. However, the canalicular enzymes were high from the second week onward (Fig. 9). Two months after transplantation, icterus finally developed and it was ascribed to partial obstruction of the reconstructed bile duct. At autopsy, the entire biliary tract was filled with inspissated bile, and most of the biliary ducts were denuded of epithelium. In contrast, the second patient remained icteric (Fig. 10) and comatose after the operation. The xe-

nograft had the same cholestatic picture as the first one despite adequate biliary anastomosis. In both patients, the jaundice was not particularly responsive to augmented immunosuppression with steroid boluses and increased maintenance doses of prednisone. Hypoalbuminemia was evident in both patients (<2 gm%) in spite of other adequate synthetic function including prothrombin time (34). Renal failure was inevitable in both patients. It developed in the first recipient after 21 days, whereas the second patient became anuric immediately after the transplantation.

Although the cause of death in both cases was multifactorial, the first recipient succumbed to ruptured intracerebral mycotic aneurysm due to disseminated aspergillosis and the second died of peritonitis secondary to an anastomotic leak at the jejunojunction of the Roux-y biliary reconstruction (34). Meanwhile, neither of the 2 hepatic xenografts provided adequate function despite the absence of significant histopathologic abnormalities. Immunoperoxidase staining revealed no evidence of reinfection of the hepatic allograft with HBV in either case.

There was little histopathologic evidence of humoral or cellular rejection of these 2 liver xenografts. Only one of the 5 biopsies obtained from the first patient (postoperative day 12) had a mild focal cellular rejection and none of the 7 biopsy samples taken from the second patient showed any definite evidence of cellular rejection by the conventional criteria used for hepatic allografts. The hepatic xenograft of both patients was entirely free of any histopathologic evidence of arteritis during the entire postoperative course. However, sludging as well as the presence of polymorphonuclear leukocytes was seen in the sinusoids of the xenografts immediately after reperfusion, compatible with the diagnosis of an aborted hyperacute rejection (36). During the first 2 weeks after transplantation, the total complement was depleted while complements C₃, C₄, and C₅ became undetectable. During this time, there was binding of IgM and IgG in the grafts with appearance of circulating immune complexes (36). After 10 days, the complement system settled down but irreversible damage may have been done which could be reflected in the form of diffuse fine microsteatosis of the graft.




Figure 10. Clinical course of the second liver xenograft (baboon-to-human) recipient.

SM, Solumedrol (methylprednisolone); PGE, prostaglandin E; Bx, biopsy; ALT, alanine aminotransferase; WBC, white blood cells. (From: Starzl TE, Tzakis A, Fung J, Todo S, Manno IR, Demetris AJ: Human liver xenotransplantation. *Xeno* 1993; 1(1):4-7. Used by permission).

After special staining procedures (immunostaining or sex identification after fluorescence in situ hybridization [FISH]), it was possible to determine if the individual cells had come from the organ donor, the recipient's own body, or both. In confirmatory investigations, the donor and recipient contributions to any specimen could be separated by polymerase chain reaction ("DNA fingerprinting") techniques.

From these analyses and from supporting laboratory experiments in animals it was clear that within minutes after restoring the blood supply of any transplant, myriads of sessile, but potentially migratory leukocytes that are part of the normal structure of all organs (passenger leukocytes), left the graft and migrated ubiquitously, while being replaced in the transplant by similar recipient immunocytes under the cover of immunosuppressive drugs (Fig. 11). In this new context, the drugs could be viewed as traffic directors, allowing movement of the white cells to and from the graft but preventing the immune destruction that is the normal purpose of this traffic.

It is not known yet how the 2 sets of white cells - a small population from the donated organ and a large one that is, in essence, the entire recipient immune system of the patient - reach an immunologic "truce." However, this is so complete in some cases that immunosuppression can be stopped, particularly after liver transplantation but less constantly with other organs. Such a stable biologic state can be induced more easily by the liver than by other transplanted organs because of the liver's higher content of the critical leukocytes that apparently included pluri-potent stem cells.

We have postulated that the previously unrecognized migration from organ allografts of donor leukocytes and their ubiquitous persistence in recipient tissues is the seminal explanation for allograft acceptance and the first stage in the development of donor specific nonreactivity (tolerance) (37-41). With this hypothesis, we undertook the augmentation of the donor leukocyte load with a penoperative infusion of nondepleted bone marrow in 16 nonconditioned recipients of livers (n=6), kidneys (n=9), and a heart including 3 diabetics who also were given pancreatic islets. All 16 have good organ transplant function and easily detectable blood macrochimerism (1-15%) after one to 12 postoperative months. None have had significant GvHD. It is too early to attempt discontinuation therapy, but serial in-vitro testing has revealed a pronounced trend to donor-specific nonreactivity (tolerance).

DISCUSSION

During the last decade, survival after liver transplantation has improved significantly with advanced medical technology, greater surgical experience, better organ preservation, and new, more effective immunosuppressive agents. The recent introduction of FK506 has further improved the survival and quality-of-life advantage of hepatic transplantation when compared with our previous experience (42). A summary of the worldwide experience with FK506 was presented during the 1991 First International Congress on FK506 and has been published elsewhere (43); the drug recently completed its "fast track" journey through the FDA.

With the evolution of a potent immunosuppressive drug like FK506, further improvement in patient and graft survival may only be possible by perfecting the surgical techniques with early detection and prompt correction of technically flawed operations (44). However, even with a perfect operation, recurrence of the primary liver disease is a major threat to graft and patient survival after liver transplantation. It is well known that candidates with either active viral hepatitis and/or liver malignancy remain at high risk of disease recurrence. The results of our cumulative experience with the prophylactic or therapeutic use of antiviral agents have been unsatisfactory (45-47). A role may emerge for thymosin, the new immunomodulator for prevention or treatment of recurrent viral hepatitis among liver allograft recipients. The survival benefit of our current protocol of treating liver recipients carrying the penoperative diagnosis of primary liver malignancy with intra-arterial and/or systemic chemotherapy have yet to be determined, but the early results are less encouraging than hoped for.

The survival outcome after liver transplantation is profoundly influenced by the recipient's condition at the time of surgery, particularly if the preterminal or terminal stages (UNOS 4 and 5) are reached. The best postoperative 2-year survival rate was in the lowest risk UNOS 1, 2, and 3 patients (83% combined) and the worst results were those in UNOS 4 and 5 (76% combined). The continuing shortage of organs for transplantation compounded by the current organ allocation policies in the United States continues to impose a significant mortality among the high-risk categories while awaiting for liver replacement (48).

The recent achievement of satisfactory long-term survival of patients treated with combined liver-intestinal and multivisceral transplantation is justification for

REFERENCES

1. Starzl TE. Introduction. Second International Workshop on FK 506. A potential breakthrough in immunosuppression: Clinical Implications. *Transplant Proc* 1990; 22:5.
2. Starzl TE, Todo S, Fung J, et al. FK 506 for human liver, kidney and pancreas transplantation. *Lancet* 1989; 2:1000.
3. Fung J, Todo S, Jain A, et al. Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. *Transplant Proc* 1990; 22:6.
4. Fung J, Todo S, Tzakis A, et al. Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression. Benefits and pitfalls. *Transplant Proc* 1991; 23:14.
5. Todo S, Fung J, Tzakis A, et al. One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. *Transplant Proc* 1991; 23:1397.
6. Venkataramanan R, Jain A, Cadoff E, et al. Pharmacokinetics of FK 506: preclinical and clinical studies. *Transplant Proc* 1990; 22:52.
7. Venkataramanan R, Jain A, Warty VW, et al. Pharmacokinetics of FK 506 following oral administration. A comparison of FK 506 and cyclosporine. *Transplant Proc* 1991; 23:931.
8. Starzl TE, Abu-Elmagd K, Tzakis A, et al. Selected topics on FK 506 with special references to rescue of extrahepatic whole organ grafts, transplantation of forbidden organs, side effects, mechanisms and practical pharmacokinetics. *Transplant Proc* 1991; 23:914.
9. Tamura K, Kobayashi M, Hashimoto K, et al. A highly sensitive method to assay FK 506 levels in plasma. *Transplant Proc* 1987; 19:23.
10. Cadoff EM, Venkataramanan R, Krajack A, et al. Assay of FK 506 in plasma. *Transplant Proc* 1990; 22:50.
11. Eghtesad B, Bronsther O, Irish W, et al. Disease gravity and urgency of need as guidelines for liver allocation. *Hepatology* (in press).
12. Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs. cyclosporine. *Transplant Proc* 1991; 23:2977.
13. Abu-Elmagd K, Fung J, Alessiani M, et al. The effect of graft function on FK 506 plasma levels, dosages and renal function, with particular reference to the liver. *Transplantation* 1991; 52:71.
14. Abu-Elmagd K, Fung J, Draviam R, et al. Four-hour versus 24 hour intravenous infusion of FK 506 in liver transplantation. *Transplant Proc* 1991; 23:2767.
15. Jain AB, Fung J, Venkataramanan R, et al. FK 506 dosage in human organ transplantation. *Transplant Proc* 1990; 22:23.
16. Takaya S, Iwaki Y, Starzl TE. Liver transplantation in cytotoxic crossmatch cases using FK 506, high dose steroids, and prostaglandin E₁. *Transplantation* 1992; 54:927.
17. Jain A, Fung J, Todo S, et al. Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. *Transplant Proc* 1991; 23:928.
18. Shapiro R, Fung JJ, Jain AB, et al. The side effects of FK 506 in humans. *Transplant Proc* 1990; 22:35.
19. Alessiani M, Kusne S, Martin M, et al. Infections with FK 506 immunosuppression: Preliminary results with primary therapy. *Transplant Proc* 1990; 22:44.
20. Alessiani M, Cillo U, Fung J, et al. Adverse effects of FK 506 overdosage after liver transplantation. *Transplant Proc* 1993; 25:628.
21. Eidelman BH, Abu-Elmagd K, Wilson J, et al. Neurologic complications of FK 506. *Transplant Proc* 1991; 23:3175.
22. Alessiani M, Kusne S, Martin M, et al. Infections in adult liver transplant patients under FK 506 immunosuppression. *Transplant Proc* 1991; 23:1501.
23. Green M, Tzakis A, Reyes J, et al. Infectious complications of pediatric liver transplantation under FK 506. *Transplant Proc* 1991; 23:3038.
24. Reyes J, Tzakis A, Green M, et al. Post-transplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression. *Transplant Proc* 1991; 23:3044.
25. Manez R, Martin M, Raman V, et al. Fluconazole therapy in transplant recipients under FK 506 therapy. *Transplantation* (in press).
26. Jain A, Venkataramanan R, Lever J, Warty V, et al. FK 506 and pregnancy in liver transplant patients. *Transplantation* (in press).
27. Murase N, Kim D, Todo S, et al. Induction of liver, heart and multivisceral graft acceptance with a short course of FK 506. *Transplant Proc* 1990; 22:74.
28. Murase N, Demetris AJ, Matusuzaki T, et al. Long survival in rats after multivisceral versus isolated small bowel allotransplantation under FK 506. *Surgery* 1991; 110:87.
29. Todo S, Tzakis A, Abu-Elmagd K, et al. Cadaveric small bowel and small bowel-liver transplantation in humans. *Transplantation* 1992; 53:369.
30. Starzl TE, Todo S, Tzakis A, et al. The many faces of multivisceral transplantation. *Surg Gynecol Obstet* 1991; 172:335.
31. Abu-Elmagd K, Fung JJ, Reyes J, et al. Management of intestinal transplantation in humans. *Transplant Proc* 1992; 24:1243.
32. Abu-Elmagd K, Todo S, Tzakis A, et al. Intestinal transplantation: 3 years clinical experience. *Surg Gynecol Obstet* (in press).
33. Starzl TE, Fung J, Tzakis A, Todo S, et al. Baboon to human liver transplantation. *Lancet* 1993; 341:65.
34. Starzl TE, Tzakis A, Fung JJ, Todo S, Manno IR, Demetris AJ. Human liver xenotransplantation. *Xeno* 1993; 1:4.
35. Starzl TE, Demetris AJ. Development of the replacement operation. In: *Liver Transplantation, Year Book Medical Publishers, Inc. Chicago, 1989, 3.*
36. Starzl TE, Tzakis A, Fung JJ, et al. Prospects of clinical xenotransplantation. *Transplant Proc* (in press).